Drug Profile
Tuxobertinib - Black Diamond Therapeutics
Alternative Names: BDTX-189Latest Information Update: 12 Oct 2022
Price :
$50
*
At a glance
- Originator Black Diamond Therapeutics
- Class Acrylamides; Antineoplastics; Morpholines; Pyridines; Quinazolines; Small molecules
- Mechanism of Action Epidermal growth factor receptor antagonists; ERBB 2 receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Solid tumours
Most Recent Events
- 03 Oct 2022 Black Diamond Therapeutics terminates the phase I/II MasterKey-01 trial in Solid tumours (Late-stage disease, Second-line therapy or greater) in USA, Denmark, France, Italy, Netherlands, Spain, Poland (PO) as the development was discontinued by the sponsor (NCT04209465) (EudraCT2020-005492-12)
- 25 Apr 2022 Discontinued - Phase-I/II for Solid tumours (Late-stage disease, Second-line therapy or greater) in Denmark, France, Italy, Netherlands, Poland, Spain (PO) (NCT04209465) (EudraCT2020-005492-12)
- 25 Apr 2022 Discontinued - Phase-I/II for Solid tumours (Late-stage disease, Second-line therapy or greater) in USA (PO)